Literature DB >> 10413093

The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant.

B Losman1, M Biller, S Olofsson, K Schønning, O S Lund, B Svennerholm, J E Hansen, A Bolmstedt.   

Abstract

We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies. In contrast Nakayama et al. [FEBS Lett. (1998) 426, 367-372], using a virus with an identical V3 region, suggested that elimination of this particular glycan reduced the ability of T-tropic HIV to bind to CXCR4 and hence its ability to infect T cell lines. We therefore re-examined the ability of a mutant virus, lacking the N306 glycan, to replicate in various types of cells and found no change in co-receptor usage for mutant virus. The ability of mutant virus to replicate or to induce syncytia in infected cells was similar to that of wild type virus. These results corroborate our original observation, confirming that the induced mutation in the N306 glycosylation site neither impairs nor improves the ability of mutant virus to replicate in permissive cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413093     DOI: 10.1016/s0014-5793(99)00740-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.

Authors:  M Gordon; T De Oliveira; K Bishop; H M Coovadia; L Madurai; S Engelbrecht; E Janse van Rensburg; A Mosam; A Smith; S Cassol
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.

Authors:  R A Ogert; M K Lee; W Ross; A Buckler-White; M A Martin; M W Cho
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  The comparison of genetic variation in the envelope protein between various immunodeficiency viruses and equine infectious anemia virus.

Authors:  Qing Yuan; Chang Liu; Zhipin Liang; Xueqing Chen; Danhong Diao; Xiaohong Kong
Journal:  Virol Sin       Date:  2012-07-28       Impact factor: 4.327

4.  Mutation of a Single Envelope N-Linked Glycosylation Site Enhances the Pathogenicity of Bovine Leukemia Virus.

Authors:  Alix de Brogniez; Amel Baya Bouzar; Jean-Rock Jacques; Jean-Philippe Cosse; Nicolas Gillet; Isabelle Callebaut; Michal Reichert; Luc Willems
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

5.  Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.

Authors:  Rafael S Depetris; Jean-Philippe Julien; Reza Khayat; Jeong Hyun Lee; Robert Pejchal; Umesh Katpally; Nicolette Cocco; Milind Kachare; Evan Massi; Kathryn B David; Albert Cupo; Andre J Marozsan; William C Olson; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

6.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.

Authors:  Ingo Thordsen; Svenja Polzer; Michael Schreiber
Journal:  BMC Infect Dis       Date:  2002-12-19       Impact factor: 3.090

8.  The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop.

Authors:  Natasha T Wood; Elisa Fadda; Robert Davis; Oliver C Grant; Joanne C Martin; Robert J Woods; Simon A Travers
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.